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Abstract Mammalian telomeric DNA consists of tandem
repeats of the sequence TTAGGG associated with a spe-
cialized set of proteins, known collectively as Shelterin.
These telosomal proteins protect the ends of chromosomes
against end-to-end fusion and degradation. Short telomeres
in breast cancer cells confer telomere dysfunction and this
can be related to Shelterin proteins and their level of
expression in breast cancer cell lines. This study investi-
gates whether expression of Shelterin and Shelterin-asso-
ciated proteins are altered, and influence the protection and
maintenance of telomeres, in breast cancer cells. 5-aza-20-
deoxycytidine (5-aza-CdR) and trichostatin A (TSA) were
used in an attempt to reactivate the expression of silenced
genes. Our studies have shown that Shelterin and Shelterin-
associated genes were down-regulated in breast cancer cell
lines; this may be due to epigenetic modification of DNA
as the promoter region of POT1 was found to be partially
methylated. Shelterin genes expression was up-regulated
upon treatment of 21NT breast cancer cells with 5-aza-CdR
and TSA. The telomere length of treated 21NT cells was
measured by q-PCR showed an increase in telomere length
at different time points. Our studies have shown that down-
regulation of Shelterin genes is partially due to methylation
in some epithelial breast cancer cell lines. Removal of
epigenetic silencing results in up-regulation of Shelterin
and Shelterin-associated genes which can then lead to
telomere length elongation and stability.
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Introduction
Telomeres are made up of G-rich nucleotide repeats of the
sequence (TTAGGG)n bound by associated proteins at the
ends of the chromosomes of eukaryotic and all mammalian
cells [1, 2]. Telomeric DNA together with the associated
telosomal proteins, collectively known as the Shelterin
complex, is essential for the overall maintenance of genome
integrity and prevents DNA degradation and chromosome
end-to-end fusions [3]. The Shelterin or telosome, consist of
the six proteins TRF1, TRF2, POT1, TIN2, TPP1 and RAP1,
it packages telomeric DNA and helps to hide the chromo-
some ends from being recognized as sites of DNA damage
during DNA replication [4]. TRF1 and TRF2 bind to the
double stranded T-loop of telomeric DNA and are impli-
cated in maintaining the formation of the T-loop structure,
while POT1 interacts with single-stranded TTAGGG
repeats at the 30 overhang, as well as in the D-loop of the
T-loop configuration. TRF1 and TRF2 recruit TIN2, RAP1,
TPP1, and POT1 to telomeric DNA [4]. Shelterin proteins
interact with a number of other factors known as Shelterin-
associated proteins that can influence chromosome end
integrity and dynamics. These Shelterin-associated proteins
are known as TNKS1, TNKS2, SMG6, and TEP1 [5–7].
Telomerase is a unique cellular ribonucleoprotein (RNP)
complex that synthesizes TTAGGG sequence repeats onto
the 30 end of chromosome terminals [1, 8]. The core enzyme
contains two subunits: telomerase reverse transcriptase
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(TERT) and telomerase RNA (TR) [9]. The TR molecule,
complementary to the telomeric repeats, is an important
element of the telomerase enzyme; it consists of an RNA
template region that facilitates adding telomeric repeats
through the action of the reverse transcriptase catalytic
subunit of telomerase (TERT) [10]. These two subunits can
bind with additional proteins that together expedite syn-
thesis and elongation of telomeric DNA [8]. In the absence
of telomerase, i.e., in most normal adult somatic cells, the
hexanucleotide repeats decrease after each cell division;
therefore cells undergo senescence when the lengths of
telomeres are reduced to a critical level. In addition, telo-
mere loss causes genome instability, resulting in destruction
of cell-cycle control, one of the hallmarks of cancer [11]. In
most cancer cells, telomerase has been reactivated and
prevents cancer cells from entering senescence [11]. Con-
sequently, the activation of telomerase is an important step
in development of human cancers [7]. In addition, telomere
dysfunction through telomere shortening and/or dysregula-
tion of telomeric DNA-binding proteins (Shelterin), occurs
in both the in situ and invasive stages of many cancers, such
as breast cancer [12]. Previous noteworthy studies reported
different expression levels of Shelterin and Shelterin-asso-
ciated genes in different human cancers [7, 11, 13]. Salhab
et al. [7] indicated over-expression of TNKS1, hTERT,
EST1, and TEP1 and down-regulation of TNKS2 and POT1
mRNA levels in breast cancer tissues compared with normal
breast tissues. Moreover, the lower expression of TRF1 and
TRF2 was found to be associated with the development and
progression of breast cancer. However, findings by Hu et al.
[14] in other cancers appeared to be contradictory to this.
They demonstrated significant over-expression of TRF1,
TRF2, and TIN2 in precancerous lesions, gastric cancer
tissues, and lymph node metastases in comparison with
normal gastric mucosa tissues [14]. In addition, recently
published data by Lu et al. [11], showed over-expression of
POT1 mRNA levels in gastric cancer tissues.
Epigenetic modifications such as abnormal DNA meth-
ylation and modifications of histones play an important role
in cancer development [15, 16]. In particular, methylation
of DNA within promoter regions serves to suppress the
expression of genes that could play a critical role in
inhibiting tumorigenesis [17, 18]. Histone acetylation and
deacetylation catalyzed by the enzymes histone acetyl
transferases (HATs) and histone deacetylases (HDACs),
respectively, are also important in maintaining the balance
between silent and transcriptionally active chromatin. It
has been shown that disruption of HATs or HDACs activity
can contribute several cancers [19, 20].
In this study, based on the scenario mentioned above, it is
hypothesized that down-regulation of Shelterin and Shelterin-
associated genes might be under the control of DNA meth-
ylation and histone modifications. Therefore, the expression
of hypermethylated genes can be actively restored after
treatment with DNA methylation inhibitors, such as 5-aza-20-
deoxycytidine (5-aza-CdR). In addition, trichostatin A (TSA),
a potent inhibitor of mammalian HDAC Class I and II
enzymes, can be used to modify gene expression by pre-
venting acetylation of histones within chromatin. For this
reason, inhibition of histone acetylation by TSA has been used
successfully as an anticancer drug [21, 22]. The effect of these
drugs on Shelterin and Shelterin-associated genes was
investigated in the breast cancer cell line 21NT.
Materials and methods
Cell culture conditions, reverse transcription,
and quantitative real-time PCR
21NT, 21MT-2, and PB1 breast cancer cell lines were grown
in modified eagle’s alpha (MEM) medium plus 10 % fetal
calf serum (FCS), 1 % glutamax, 1 % HEPES, 1 % NEAA,
and 1 ll/ml epithelial growth factor (EGF). GI101, BT-20,
HS578-T, BT474, MTSV1-7, and MCF-7 cells were cul-
tured in DMEM/F12 containing 10 % FCS and 1 % gluta-
max, 0.5 lg/ml hydrocortisone whereas HCC1143, LY-R
and LY-S were grown in RPMI/1640 plus 10 % FCS and
normal mammary epithelial cell strain (LONZA) were
grown in MEGM medium with recommended supplements
(Table 1). All cell lines were cultured in fully humidified
incubators set at 5 % CO2 and 37C. RNA was extracted
from cells using an RNeasy Mini kit (QIAGEN) and cDNA
was synthesized from 1 lg total RNA using Superscript
reverse transcriptase enzyme (Invitrogen). Quantitative real-
time reverse transcriptase PCR (qRT-PCR) was performed
on the 7900HT Fast Real Time PCR machine and 19
SYBR green master mix (Applied Biosystems) that include
5 lM primers (Table 2) and 1 ll of cDNA.
DNA isolation and methylation-specific PCR
Genomic DNA was extracted, using the WizardTM Geno-
mic DNA Kit and protocol (Promega). MethylcodeTM Bi-
sulphite conversion Kit (Invitrogen) was used for bisulphite
treatment of DNA samples. Methylation-specific PCR
(MSP) analysis was performed for POT1 using primers
(Table 3) specific for methylated and unmethylated DNA
products. The MSP products were run on 2 % agarose gels
and visualized using ethidium bromide (0.5 lg/ml).
Cell lines, maintenance, treatment, cell viability,
and qRT-PCR
To determine the optimal drug dose, 3 9 105 21NT cells
were seeded into 6-well plate. Cells that were treated with
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5-aza-CdR (5 lM, Sigma, St. Louis, MO) and TSA
(Sigma) (5, 15, 25, 50, and 100 ng/ml) were stained with
Trypan blue (Invitrogen). Stained blue cells were scored as
dead cells and unstained bright cells as viable cells. The
cell viability was determined by the following formula: No.
of viable cell/Total no. of cells 9 100. TSA at 50 ng/ml
was judged as being the best concentration to use in all
experiment. The 21NT cell line was plated at a density of
1 9 105 in p100 culture dish, 24 h after plating; the cells
were randomly assigned into treatment and control groups.
Treatment included 5-aza-CdR (5 lM) for 48 h, 72 h,
3 weeks and 2 months, either alone or in combination with
TSA (50 ng/ml). TSA was added only during the last 16 h
of treatment. For control group, one plate was treated with
0.02 % DMSO. The short-term (48 and 72 h) and long-
term (3 weeks and 2 months) effects of the drugs on the
mRNA levels of Shelterin and Shelterin-associated genes
were assessed using qRT-PCR in order to compare the
difference between each time points of the treatment.
Telomere length measurement by q-PCR
In order to determine telomere length, a real-time PCR
technique was used. The relative telomere length was
compared with that of the single copy gene (36B4 which
encodes the acidic ribosomal phosphoprotein PO) [23].
Genomic DNA was extracted from 21NT-treated cells and
the normal human mammary epithelial cell strain (HMEC)
using the WizardTM Genomic DNA Kit as described pre-
viously. 19 Power SYBER Green PCR Master Mix
(Applied Biosystems), 0.5 lM primes with 5 ng/ll sample
DNA was used (Table 4).
Stable transfection, qRT-PCR, and western blots
analysis
One day prior to transfection, 15 9 105 21NT cells were
seeded into p100 tissue culture dishes. Cells were then
transfected with the plasmid vector pcDNA-POT1/FRT/
Table 1 Description of different cell lines and normal mammary cell strains (HMECs)
Cell lines Patient
age
Histopathological
diagnosis
Tumor
stage
Primary site Growth media References
21NT 36 PDC Primary Breast MEM [35]
21MT-2 36 PDC Metastatic Breast MEM [35]
GI101 57 IDC III Breast DMEM/F12 without
hydrocortisone
–
BT-20 74 IDC – Breast DMEM/F12 without
hydrocortisone
[36]
HS578-T 74 IDC – Breast DMEM/F12 without
hydrocortisone
[37]
BT474 60 IDC – Breast DMEM/F12 without
hydrocortisone
[38]
MCF-7 69 IDC IV Pleural effusion DMEM/F12 without
hydrocortisone
[39]
HCC1143 52 PDC II Breast RPMI/1640 [40]
MTSV1-7 – Normal immortalized
mammary gland
– Breast DMEM/F12 with
hydrocortisone
[41]
PB1 36 PDC Primary Breast MEM [35]
PC3 62 Prostatic adenocarcinoma IV Prostate F12 [42]
LY-R – Mouse lymphoma,
radiosensitive
– Lymphoma RPMI/1640 Dr Andrzeg Wojcik
University of Warszawa,
Poland
LY-S – Mouse lymphoma, normal
radiosensitive
– Lymphoma RPMI/1640 Dr Andrzeg Wojcik
University of Warszawa,
Poland
HMEC – Normal human mammary
epithelial cell strain
– Breast MEGM [43]
Normal
commercial
Tissue
78 FirstChoice Human
breast total RNA
– Breast – AM6952 (Applied
Biosystems)
PC3/hTERT 62 Prostatic adenocarcinoma – Derived from PC-
3 telomerised
F12 Professor Newbold group
(Brunel University)
PDC primary ductal carcinoma, IDC infiltrating ductal carcinoma
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V5-His-TOPO (a kind gift from Roger Reddel) and empty
vector (pcDNA3.1/hygro plasmid kindly provided by Dr.
Evgeny Makarov) using GeneJuice Transfection Reagent
(Novagen) according to the manufacturer’s protocol. This
vector contains hygromycin for selection in mammalian
cells for stable transfection. POT1 overexpression was
quantified using qRT-PCR (mRNA) and western blot
(protein) analysis. For western blot analysis, cell pellets
were lysed on ice using RIPA (radioimmunoprecipitation
assay buffer, Sigma) buffer containing 19 protease inhib-
itor (Thermo). Protein concentrations were measured using
the PierceTM BCA Protein Assay Kit (Thermo Scientific).
Samples (prepared in 49 Laemmle buffer containing
1.5 M Tris–Cl pH 6.8, glycerol, b-mercaptoethanol, SDS,
1 % bromophenol blue) containing 50 lg proteins were
separated on a ready-made 12 % precast acrylamide gel
(Bio-Rad) and were blotted onto ready-made Mini PVDF
transfer membrane (Bio-Rad) using the Trans-Blot Tur-
boTM apparatus (Bio-Rad) according to the manufacturer’s
protocol. The membrane was hybridized against human
POT1 (1:5000, Abcam) and b-actin (1:10,000, Sigma)
antibodies and the signals were detected by ECL plus
(enhanced chemiluminescence) kit (GE Healthcare).
Telomerase enzyme activity
All transfected cell pellets were re-suspended in CHAPS
lysis buffer (TRAPEZE 19 CHAPS Millipore Company).
The protein concentration of samples was determined using
the PierceTM BCA Protein Assay Kit (Thermo Scientific)
according to the manufacturer’s protocol. Reaction mix-
tures for each of the samples to be analyzed were made up
using the following components: 19 standard iTaqTM
Universal Syber-green (BIO-RAD), 0.05 lg/ll of
anchored primer (ACX primer) (50-GCGCGG (CTTACC)
3CTAACC-30), 0.1 lg/ll of telomerase primer (TS Primer)
(50-AATCCGTCGAGCAGAGTT-30), and 250 ng/ll of
protein samples. The reaction mixture was first incubated at
Table 3 MSP primer sequences of POT1 promoter for PCR products
Gene/assay Forward primer (50 ? 30) Reverse primer (50 ? 30) Product size (bp)
POT1-M AGAAAGGTTTTGTTTATAGGAGT CCAATAACTTTCCAACTTTCGTA 118
POT1-U AAGGTTTTGTTTATAGGAGTTTT CCCAATAACTTTCCAACTTTCAT 116
M methylated, U unmethylated
Table 2 Shelterin and
Shelterin-associated primer
sequences for use in real-time
PCR
F foward, R reverse
Primer name Primer sequence (50 ? 30) Product
length (bp)
Accession
number
TIN2, -F TTCTGGCTGCCATGGAAAAG 108 NM_012461
TIN2, -R GCTGCATCCAACTCAGCACAT
TPP1, F TTAGCGCTGTGTGTGTGCTCTT 101 NM_001082486
TPP1, R CCGAACGGTTCAGCACATATTT
POT1, -F GAGAACAAGCGACTATGCCCA 104 NR_003102
POT1, -R ACCCTAGGAAGAGTTTAGGCGG
TRF1, -F ATGCTCGATTTCCTCTGCCTC 101 NM_003218
TRF1, -R CCATGAATAATAGCCTCTGCGC
TRF2, F AAAACGAAAGTTCAGCCCCG 101 NM_005652
TRF2, R GCTGTCCTCCTCCAAGACCAAT
RAP1, F ACCCTGCTCTTTGGCTGTTCT 101 NM_018975
RAP1, R TGTGTGCGCGTTTTAAGGAA
TNKS1, F TCAGTGTCTCTCCCAATGGCAC 103 NM_003747
TNKS1, R TGTTTGCAAGGCCATTTACAGG
TNKS2, F CCCAACACTGCTCAATTGTCAC 101 NM_025235
TNKS2, R GCAACGAGTGGCCTTTAAATTC
TEP1, F TGCCAGGCCGCACTGTCTTG 136 NM_7110
TEP1, R ACCTGCTCCGCCCTCGTGAT
SMG6, -F TCCCAGCAACCCCTTACATCT 115 NM_173156
SMG6, -R AAGCCGGCACAGCTTTTGTAG
GAPDH-F GAAGGTGAAGGTCGGAGT 226 N/A
GAPDH-R GAAGATGGTGATGGGATTTC
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25C for 20 min to allow the telomerase in the protein
extracts to elongate to the TS primer by adding TTAGGG
repeat sequence. PCR was then started at 95C for 10 min
to activate Taq polymerase followed by a two-step PCR
amplification of 35 cycles at 95C for 30 s and 60C for
90 s. Telomerase activity is reported as standard cell
equivalents. To quantify telomerase activity, a standard
curve was generated from serially diluted telomerase-
positive prostate cell line; PC-3/hTERT (106-102). All real
time amplification was carried out using an ABI Prism
7900HT (Applied Biosystems).
Results
Expression of Shelterin and Shelterin-associated genes
in breast cancer cell lines and normal breast tissue
Maintenance and regulation of chromosome ends, at the
telomere is fundamental for genome stability. The rela-
tionship between telosomal DNA-binding proteins and
telomere length maintenance has become a popular area of
interest recently. There have been a limited number of
findings looking at the relationship between telomere
length and Shelterin genes in breast cancer. Salhab et al.
(2008) demonstrated an increase in the mRNA levels of
TNKS1, hTERT, EST1, and TEP1 in breast cancer tissues
whereas TNKS2 and POT1 were down-regulated in com-
parison with normal breast tissue [7]. Our group reported
that POT1, TRF1, TRF2, SMG6, TIN2, TEP1, TNKS2, and
RAP1 were significantly down-regulated at the mRNA
level in breast cancer cell lines (MCF-7, GI101, BT474,
21MT-2, MTSV1-7, HCC1143, BT20, PB1, HS578-T, and
21NT) a prostate cancer cell line in comparison with RNA
extracted from normal mammary breast tissue (P \ 0.05,
P \ 0.01 and P \ 0.001 correspondingly) (Fig. 1a–f and
Fig. S1). However, interestingly, TPP1 mRNA levels were
higher in most breast cancer cell lines compared with
normal breast tissue (P \ 0.05 and P \ 0.01 correspond-
ingly) (Fig. 1c).
Detection of DNA methylation of POT1 promoter
region in breast cancer cell lines
Several cellular factors (i.e., mutation, DNA methylation,
histone acetylation, chromatin remodeling, etc.) in theory
could affect the expression of Shelterin and Shelterin-asso-
ciated genes in breast cancer cell lines. Based on previous
published data and our results, POT1 mRNA was found to be
significantly down-regulated in malignant breast tissues and
cancer cell lines [7]. Moreover, with regard to the hypothesis
of a critical role of POT1 in telomere length maintenance
[24], this gene was chosen for further investigation. The
promoter regions of POT1 gene in breast cancer cell lines
were analyzed to investigate whether methylation was
responsible for the down-regulation observed. MSP primers
were then designed to look for evidence of DNA methylation
in the promoter of POT1 in the normal mammary cell strains
(HMEC) and the breast cancer cell lines. As evident in
Fig. 2a, the POT1 promoter region shows a partial methyl-
ation in breast cancer cell lines. MSP showed that the POT1
promoter contains more methylated DNA in 21NT, BT474,
21MT2, and PB1 in comparison with the remainder breast
cancer cell lines and HMEC control.
Up-regulation of Shelterin and Shelterin-associated
genes by 5-aza-CdR and TSA
In order to determine the best concentration of TSA to use on
21NT, an optimization experiment was carried out. Cells were
treated with TSA between 5 and 100 ng/ml with 5 lM 5-aza-
CdR for 48 h and a cell viability assay was carried out to look
at cell survival. TSA at 50 ng/ml with 5 lM 5-aza-CdR
reduced the cell viability to 78 % (Fig. 2b), whereas the
lowest percentage of cell survival was observed in cells treated
with 100 ng/ml TSA and 5 lM 5-aza-CdR (64 %). Moreover,
cells treated with the combination of 50 ng/ml TSA and 5 lM
5-aza-CdR showed the highest Shelterin expression level
(e.g., POT1) among the aforementioned concentrations.
Consequently, 50 ng/ml was judged as being the best con-
centration to use as it gave the best trade-off between cell
Table 4 Oligomers used for telomere length assay in 21NT-treated and normal cells [23]
Oligomer name Oligomer sequence (50 ? 30) Amplicon
size (bp)
Telomere standard (human/rodent) (TTAGGG)14 84
36B4 standard (human) CAGCAAGTGGGAAGGTGTAATCCGTCTCCACAGACAAG
GCCAGGACTCGTTTGTACCCGTTGATGATAGAATGGG
75
Telo-F (human/rodent) CGGTTTGTTTGGGTTTGGGTTTGGGTTTGGGTTTGGGTT [76
Telo-R (human/rodent) GGCTTGCCTTACCCTTACCCTTACCCTTACCCTTACCCT [76
36B4-F (human) CAGCAAGTGGGAAGGTGTAATCC 75
36B4-R (human) CCCATTCTATCATCAACGGGTACAA 75
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survival and expression (Fig. 2b, c). Treatment of 21NT
breast cancer cell lines with 5 lM 5-aza-CdR and 50 ng/ml
TSA over 48 h, lead to increased expression of POT1 and
TIN2 as compared with the DMSO sample (P \ 0.05)
(Fig. 3a, b). In contrast, the up-regulation of TNKS2, TRF1,
TRF2, and RAP1 did not reach the statistical significance (Fig.
S2). However, 21NT cells treated solely by TSA did not show
up-regulation of TNKS2, TRF2, and RAP1 (Fig. S2). Treat-
ment with 5-aza-CdR alone resulted in up-regulation of all the
above genes except TRF1. Indeed, TPP1 after 48 h of treat-
ment with 5-aza-CdR increased by 4-fold when compared
with DMSO and untreated controls (P \ 0.05) (Fig. 3c).
Effects of prolonged treatment of 21NT cells with 5-
aza-CdR and TSA on transcription level of POT1
and TIN2
The preliminary results showed significantly increased
expression of POT1 and TIN2 mRNA (P \ 0.05)
following 5-aza-CdR and 5-aza-CdR/TSA treatment
(Fig. 3a, b). Therefore, we sought to investigate long-
term treatment of 21NT cells to identify whether the
expression of these genes may possibly change after
longer period of exposure. We examined the expression
of POT1 and TIN2 after treatment with 50 ng/ml TSA
and 5 lM 5-aza-CdR for 48 h, 72 h, 3 weeks, and
2 months in 21NT cells. The results indicate that treat-
ment of 21NT cells significantly increased transcription
levels of POT1 and TIN2 upon treatment with TSA,
5-aza-CdR alone, and in combination with 5-aza-CdR/
TSA after different time points. The result showed that
the expression of POT1 and TIN2 after 48 h, 72 h, and
3 weeks of treatment with TSA and 5-aza-CdR/TSA was
over 4-fold higher than in 21NT untreated cells
(P \ 0.05, P \ 0.01, and P \ 0.001 correspondingly).
Nevertheless, up-regulation of POT1 and TIN2 after
2 months treatment did not reach the statistical signifi-
cance (Fig. 3d, e).
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Fig. 1 Expression of Shelterin genes in breast and prostate cancer
cell lines. The level of all Shelterin genes normalized against GAPDH
mRNA in breast cancer cell lines compared with prostate cancer and
normal breast tissue, determined by a quantitative reverse transcrip-
tion polymerase chain reaction. a–c POT1, TIN2, and TPP1 mRNA
expression determined by qRT-PCR in breast cancer cell lines, a
normal breast tissue and a prostate cancer cell line (PC-3). d–f qRT-
PCR analysis of RAP1, TRF1, and TRF2 mRNA isolated from cancer
cell lines. The PC-3 cell line was included for comparison. Normal
breast tissue (cDNA) was used as the calibrator for all graphs. Error
bars represent SEM. *P \ 0.05, **P \ 0.01, ***P \ 0.001
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Telomere length measurement by q-PCR following
epigenetic changes to the Shelterin genes
To date, no previous investigations have reported on the
possible effects of 5-aza-CdR and TSA can have on telomere
length maintenance in cancer cells. Hence, the average
telomere length was measured by q-PCR in treated and
untreated 21NT cells, DMSO-treated (control) at different
time points, in order to investigate whether the up-regulation
of Shelterin genes such as POT1, TIN2, and TPP1 has an
effect on average telomere length. As shown in Fig. 3f short-
term (72 h) and 3 weeks treatment of 21NT cells with 5-aza-
CdR showed increase telomere lengths ranging from 4.5 to
4.7 kb in comparison with untreated and DMSO-treated
controls whose telomere lengths were around 2 kb. The
mean telomere length of the combination treatment of 21NT
cells with 5-aza-CdR and TSA for 72 h and 3 weeks had a
significant telomere length increase (Fig. 3f) to about 3.4 and
3.7 kb, respectively (P \ 0.05). BT474 and MCF7, which
also had partial methylation of the POT1 promoter, were then
treated as above for 72 h. Both cell lines also showed an
increase in telomere length (Fig. S3) therefore confirming
that this is a common occurrence following treatment with
5-aza-CdR and TSA. To our surprise, treatment of HMEC
with 5-aza-CdR and TSA resulted in a substantial increase in
telomere length. This observation is consistent with recent
report showing that treatment of cloned blastocysts and pigs
by TSA resulted in telomere length elongation [25]. In
addition, Blasco and her group reported that mouse
embryonic stem cells genetically deficient in DNA methyl-
transferases at subtelomeric regions resulted in dramatically
elongated telomere length [26].
Over-expression of POT1 facilitates telomere length
elongation in 21NT cells
Our data may suggest that the regulation of the Shelterin
protein complex is needed to maintain telomere length reg-
ulation in breast cancer cell lines. Previous studies showed
that reduction of POT1 by RNAi results the loss of the 30
overhangs [27]. Furthermore, it had also been observed that
over-expression of POT1 in telomerase-positive cells
resulted in telomere length elongation [24, 28].
In order to evaluate the effects of POT1 (variation 1, full
length) over-expression in 21NT cancer cells, these cells
were transfected with human POT1. As shown in Fig. 4a,
POT1 mRNA levels were elevated 3- to 4-fold in the
POT1-1/pcDNA5 and POT1-3/pcDNA5 clones compared
with non-transfected 21NT cells and empty vector controls.
This difference was statistically significance when com-
pared with the level in non-transfected 21NT cells
(P \ 0.5). Western blot analysis confirmed overexpression
of POT1 in transfected 21NT cells at the protein level
(Fig. 4b). In order to obtain a better and clear under-
standing of the exact role and function of POT1 in pro-
tection and maintenance of telomeres in human breast
cancer, we needed to determine whether overexpression of
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Fig. 2 a Methylation-specific PCR (MSP) analysis of the POT1
promoter in breast cancer cell lines and normal mammary epithelial
cell strain (HMEC). POT1 panel viewed from left to right. Lane 1 is
the ladder, M presence of methylated DNA, and U unmethylated. b,
c The changes in breast cancer cell viability and expression level of
POT1 after treatment with TSA and 5-aza-CdR. 21NT cells was
treated with TSA at different concentration and with a single
concentration (5 lM) of 5-aza-CdR. The cell viability assay was
performed to determine cell survival. qRT-PCR results show changes
in POT1 expression levels in 21NT cells after treatment with TSA at
different concentrations and 5-aza-CdR for 48 h
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POT1 may play a role in telomere length maintenance. For
this analysis, the q-PCR technique was used. The average
telomere length of 21NT non-transfected and empty vector
control clones ranged from 2.5 to 3 kb, while the POT1
over-expressing clones were between 4 and 5 kb. This
represents an increase in telomere length of approximately
2 kb around 4 weeks after transfection (Fig. 4c). Telome-
rase activity within stable clones was measured in order to
search for a link between telomerase activity and increased
telomere elongation. The results presented in Fig. 4d, show
that approximately 2-fold reduction in telomerase enzyme
activity was observed in two stable clones compared with
21NT cells, non-transfected, and PC-3/hTERT controls.
Our data suggested that telomere elongation by POT1 is
not mediated by increased telomerase enzyme activity.
Discussion
Here, we have provided evidence that using inhibitors of
methyltransferases (5-aza-CdR) has the potential to cause
telomere elongation. The National Cancer Institute data-
base reported that these epigenetic modification agents
have been used as anti-cancer drugs in about 100 clinical
trials [29]. The drugs have been used to treat different types
of leukemia, sickle cell anemia, and b-thalassemia [30]. It
0
100
200
300
400
500
Untreated DMSO
(0.02%)
Aza 5µM TSA 50ng/ml Aza+TSA
R
Q 
(%
)
POT1
*
*
0
100
200
300
400
500
Untreated DMSO
(0.02%)
Aza 5µM TSA 50ng/ml Aza+TSA
R
Q 
(%
)
TIN2
*
*
0
100
200
300
400
500
600
Untreated DMSO
(0.02%)
Aza 5µM TSA 50ng/ml Aza+TSA
R
Q 
(%
)
TPP1c *
0
200
400
600
800
48 h 72 h 3 weeks 6 weeks 2 months
R
Q 
(%
)
TIN2
DMSO (0.02%)
Aza 5µM
Aza+TSA
TSA 50ng/ml*
*
e
**
0
200
400
600
800
48 h 72 h 3 weeks 6 weeks 2 months
R
Q 
(%
)
POT1 DMSO (0.02%)
Aza 5µM
Aza+TSA
TSA 50ng/ml
*
*
*
***
*
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
Controls 72 h 3 weeks 6 weeks 2 months
N
or
m
al
iz
at
io
n 
TL
/C
op
y 
n
u
m
br
 (b
p)
HMEC1 p5
Untreated
DMSO 0.02%
5-aza-CdR 5µM
5-aza-CdR
5µM+TSA 50ng/ml
*
a b
d
f
Fig. 3 Effects of 5-aza-CdR and TSA on the expression of POT1,
TIN2, and TPP1 in the 21NT breast cancer cell line. a–c qRT-PCR
analysis of POT1, TIN2, and TPP1 mRNA levels following 5-aza-
CdR and TSA treatments in 21NT cells for 48 h. Expression of each
gene was normalized to GAPDH mRNA level. DMSO control was
used as the calibrator. RQ and error bars indicate relative quantifi-
cation and SEM. Asterisk indicates significant difference between
21NT-treated cells and DMSO control (*P \ 0.05). d, e Expression
of POT1 and TIN2 in 21NT-treated cells at different time points. The
graph represents analysis of mRNA from the indicated 21NT-treated
cells by qRT-PCR. DMSO-treated (control) was used as the
calibrator. Error bars represent SEM. Asterisk indicates significant
differences between 21NT-treated cell lines and DMSO control
(*P \ 0.05, ***P \ 0.001, and **P \ 0.01). f Effects of 5-aza-CdR
and TSA on telomere length. The analysis was performed with
untreated and DMSO-treated 21NT being used as controls, these were
compared with 21NT treated at different time points. HMEC, p5 was
used as positive control. Error bars represent SEM. Asterisk indicates
difference between DMSO-treated cells and 21NT-treated cell lines
(*P \ 0.05)
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has been shown that 5-aza-cdR has a global effect on gene
expression in acute myeloid leukemia [31] therefore we
can assume that 5-aza-CdR has a global effect on the
expression of Shelterin and Shelterin-associated genes as
well as DNA methyltransferases enzymes [29]. Our study
has shown that in breast cancer, Shelterin expression can be
down-regulated through epigenetic modification of DNA
and histone proteins. Results obtained have shown that the
use of chemotherapeutic epigenetic modifying drugs, such
as 5-aza-CdR and TSA, induce and increase the expression
of several Shelterin and Shelterin-associated genes in
breast cancer cell lines. Up-regulation of these genes ulti-
mately leads to an increase in telomere length. The effect
of 5-aza-CdR and TSA on mammalian telomeres has not
been widely reported in the literature to date making the
results presented here novel. We can now speculate on how
the use of therapeutic agents such as 5-aza-CdR and TSA
to increase telomere lengths of cancer cells may benefit
clinical outcome. Research into the role of Shelterin and
telomerase in cancer has found that telomerase re-activa-
tion functions to maintain telomeres at a critically short
length [32]. Telomeres in this unstable state are still prone
to genetic damage via end-to-end fusions and transloca-
tions. This will have the effect of damaging the genome of
the cancer cell giving rise to further clonal evolution and a
more advanced disease. If drugs such as 5-aza-CdR and
TSA are used to treat cancer, they could induce telomere
lengthening. This may have the effect of stabilizing the
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Fig. 4 a Over-expression of POT1 (variation 1) after transfection of
21NT cells. Data shows the average expression level of POT1 in
21NT non-transfected control, five vector control clones and two
clones after POT1 transfection, relative to GAPDH. The non-
transfected 21NT cells were used as the calibrator. RQ indicates
relative quantification and error bars represent SEM. Asterisk
indicates significant difference between 21NT cells and transfected
cells (*P \ 0.05). b Western blots analysis of POT1 in 21NT
transfected and control cell. A 12 % SDS-PAGE gel showing POT1
protein expression in transfected 21NT cells, two empty vector
controls, PC-3, non-transfected 21NT and normal mammary epithelial
cell strain (HMEC-p10). b-Actin was used as a loading control.
c Telomere length in 21NT transfected and control cell lines by
q-PCR. Analysis was performed with non-transfected 21NT, two
vector control clones, two stable clones, and HMEC1 p5 and PC-3
controls. Error bars represent SEM. d Quantitative telomerase
activity. All values were acquired based on CT values. Relative
telomerase enzyme activity was obtained utilizing a standard curve
generated by the serial dilution of PC-3/hTERT. The analysis was
performed with the highest telomerase enzyme activity assigned to
the PC-3/hTERT sample and the activity in the unknown worked out
as a percentage of the PC-3/hTERT sample. Error bars represent
SEM. Asterisk indicates significant difference between 21NT cells
and transfected cells (*P \ 0.05)
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telomere and reducing the amount of genetic damage the
cell will undergo thereby stopping the clonal evolution of
the cancer cell population. These tumors may be more
susceptible to further treatment as a result. Alternatively,
lengthening the telomeres of cancer cells may give rise to
chemo-resistant tumors. In our study, HMEC also showed
an increase in telomere lengths upon treatment with 5-aza-
CdR and TSA, this was unexpected as these cells already
have long telomeres. HMEC’s are known to have residual
telomerase activity [33], this together with the added drugs
could be responsible for the telomere elongation observed
in these cells. Targeting Shelterin protein components may
be more effective that targeting telomerase [45], especially
POT1 which is implicated to regulate telomere length and
capping [4, 34]. We found that telomere elongation by
over-expression of POT1 was not due to a direct effect of
increased telomerase activity. Colgin et al. (2003) also
observed this when they over-expressed POT1 in telome-
rase-positive cells, hence it seems likely that POT1 nega-
tively regulates telomerase activity [24, 28, 44]. In
conclusion, our results indicated that most of the Shelterin
and Shelterin-associated genes were significantly down-
regulated at the mRNA level in breast cancer cell lines.
Further investigations showed that the promoter region of
POT1 was partially methylated in breast cancer cell lines.
We observed that 5-aza-CdR and TSA treatment of HMEC,
21NT, Bt474, and MCF7 lead to an increase in telomere
lengths when compared to untreated controls.
Acknowledgments We are indebted to Professor Robert Newbold
for useful discussion and for providing the facilities to carry out this
work. We would also like to thank Alison Marriott for technical
advice on growing the cell lines. The POT1 cDNA was cloned into
the plasmid vector pcDNA-FRT/V5-His-TOPO which was kindly
provided by Roger R. Reddel (Children’s medical Research Institute,
Australia).
Conflict of interest The authors declare no conflict of interest.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and the source are credited.
References
1. Griffith JD, Comeau L et al (1999) Mammalian telomeres end in
a large duplex loop. Cell 97(4):503–514
2. Smogorzewska A, de Lange T (2004) Regulation of telomerase
by telomeric proteins. Annu Rev Biochem 73:177–208
3. Palm W, de Lange T (2008) How shelterin protects mammalian
telomeres. Annu Rev Genet 42:301–334
4. Martinez P, Blasco MA (2010) Role of shelterin in cancer and
aging. Aging Cell 9(5):653–666
5. Smith S, Giriat I et al (1998) Tankyrase, a poly(ADP-ribose)
polymerase at human telomeres. Science 282(5393):1484–1487
6. Liu Y, Snow BE et al (2000) Telomerase-associated protein
TEP1 is not essential for telomerase activity or telomere length
maintenance in vivo. Mol Cell Biol 20(21):8178–8184
7. Salhab M, Jiang WG et al (2008) The expression of gene tran-
scripts of telomere-associated genes in human breast cancer:
correlation with clinico-pathological parameters and clinical
outcome. Breast Cancer Res Treat 109(1):35–46
8. Wyatt HD, West SC et al (2010) InTERTpreting telomerase
structure and function. Nucleic Acids Res 38(17):5609–5622
9. Meyerson M, Counter CM et al (1997) hEST2, the putative
human telomerase catalytic subunit gene, is up-regulated in tumor
cells and during immortalization. Cell 90(4):785–795
10. Autexier C, Lue NF (2006) The structure and function of telo-
merase reverse transcriptase. Annu Rev Biochem 75:493–517
11. Lu L, Zhang C et al (2011) Telomerase expression and telomere
length in breast cancer and their associations with adjuvant
treatment and disease outcome. Breast Cancer Res 13(3):R56
12. Butler KS, Hines WC et al (2012) Coordinate regulation between
expression levels of telomere-binding proteins and telomere
length in breast carcinomas. Cancer Med 1(2):165–175
13. Cookson JC, Laughton CA (2009) The levels of telomere-binding
proteins in human tumours and therapeutic implications. Eur J
Cancer 45(4):536–550
14. Hu H, Zhang Y et al (2010) Expression of TRF1, TRF2, TIN2,
TERT, KU70, and BRCA1 proteins is associated with telomere
shortening and may contribute to multistage carcinogenesis of
gastric cancer. J Cancer Res Clin Oncol 136(9):1407–1414
15. Lund AH, van Lohuizen M (2004) Epigenetics and cancer. Genes
Dev 18(19):2315–2335
16. Kouzarides T (2007) Chromatin modifications and their function.
Cell 128(4):693–705
17. Das PM, Singal R (2004) DNA methylation and cancer. J Clin
Oncol 22(22):4632–4642
18. Mossman D, Kim KT et al (2010) Demethylation by 5-aza-20-
deoxycytidine in colorectal cancer cells targets genomic DNA
whilst promoter CpG island methylation persists. BMC Cancer
10:366
19. Bannister AJ, Kouzarides T (2011) Regulation of chromatin by
histone modifications. Cell Res 21(3):381–395
20. Zhang F, Li Y, Qin G (2008) Effects of trichostatin A (TSA) on
growth and gene expression in HeLa cells. J Clin Oncol
7(5):304–308
21. Drummond DC, Noble CO et al (2005) Clinical development of
histone deacetylase inhibitors as anticancer agents. Annu Rev
Pharmacol Toxicol 45:495–528
22. Meng CF, Dai DQ et al (2008) Effects of 5-Aza-20-deoxycytidine
and trichostatin A on DNA methylation and expression of
hMLH1 in ovarian cancer cell line COC1/DDP. Ai Zheng
27(12):1251–1255
23. O’Callaghan NJ, Fenech M (2011) A quantitative PCR method
for measuring absolute telomere length. Biol Proc Online 13:3
24. Yang Q, Zhang R et al (2007) Functional diversity of human
protection of telomeres 1 isoforms in telomere protection and
cellular senescence. Cancer Res 67(24):11677–11686
25. Kong Q, Ji G, et al (2014) Telomere elongation facilitated by
trichostatin A in cloned embryos and pigs by somatic cell nuclear
transfer. Stem Cell Rev 10(3):399–407
26. Susana G, Isabel J et al (2006) DNA methyltransferases control
telomere length and telomere recombination in mammalian cells.
Nat cell Biol 8(4):416–424
27. Yang Q, Zheng YL et al (2005) POT1 and TRF2 cooperate to
maintain telomeric integrity. Mol Cell Biol 25(3):1070–1080
28. Colgin LM, Baran K et al (2003) Human POT1 facilitates telo-
mere elongation by telomerase. Curr Biol 13(11):942–946
590 Breast Cancer Res Treat (2014) 145:581–591
123
29. Ghoshal K, Datta J et al (2005) 5-Aza-deoxycytidine induces
selective degradation of DNA methyltransferase 1 by a prote-
asomal pathway that requires the KEN box, bromo-adjacent
homology domain, and nuclear localization signal. Mol Cell Biol
25(11):4727–4741
30. Saunthararajah Y, Hillery CA et al (2003) Effects of 5-aza-20-
deoxycytidine on fetal hemoglobin levels, red cell adhesion, and
hematopoietic differentiation in patients with sickle cell disease.
Blood 102(12):3865–3870
31. Schmelz K, Sattler N et al (2005) Induction of gene expression by
5-Aza-20deoxycytidine in acute myeloid leukemia (AML) and
myelodysplastic syndrome (MDS) but not epithelial cells by
DNA-methylation-dependent and -independent mechanisms.
Leukemia 19(1):103–111
32. Low KC, Tergaonkar V (2013) Telomerase: central regulator of
all of the hallmarks of cancer. Trends Biochem Sci
38(9):426–434
33. Sputova K, Garbe JC et al (2013) Aging phenotypes in cultured
normal human mammary epithelial cells are correlated with
decreased telomerase activity independent of telomere length.
Genome Integr 4(4):1–8. doi:10.1186/2041-9414-4-4
34. Lu Y, Wei B et al (2013) How will telomeric complex be further
contributed to our longevity?—the potential novel biomarkers of
telomere complex counteracting both aging and cancer. Protein
Cell 4(8):573–581
35. Band V, Zajchowski D et al (1990) Tumor progression in four
mammary epithelial cell lines derived from the same patient.
Cancer Res 50(22):7351–7357
36. Lasfargues EY, Ozzello L (1958) Cultivation of human breast
carcinomas. J Natl Cancer Inst 21(6):1131–1147
37. Hackett AJ, Smith HS et al (1977) Two syngeneic cell lines from
human breast tissue: the aneuploid mammary epithelial (Hs578T)
and the diploid myoepithelial (Hs578Bst) cell lines. J Natl Cancer
Inst 58(6):1795–1806
38. Lasfargues EY, Coutinho WG et al (1978) Isolation of two
human tumor epithelial cell lines from solid breast carcinomas.
J Natl Cancer Inst 61(4):967–978
39. Soule HD, Vazguez J et al (1973) A human cell line from a
pleural effusion derived from a breast carcinoma. J Natl Cancer
Inst 51(5):1409–1416
40. Gazdar AF, Kurvari V et al (1998) Characterization of paired
tumor and non-tumor cell lines established from patients with
breast cancer. Int J Cancer 78(6):766–774
41. D’Souza B, Berdichevsky F et al (1993) Collagen-induced mor-
phogenesis and expression of the alpha 2-integrin subunit is
inhibited in c-erbB2-transfected human mammary epithelial cells.
Oncogene 8(7):1797–1806
42. Kaighn ME, Narayan KS et al (1979) Establishment and char-
acterization of a human prostatic carcinoma cell line (PC-3).
Invest Urol 17(1):16–23
43. Garbe JC, Bhattacharya S et al (2009) Molecular distinctions
between stasis and telomere attrition senescence barriers shown
by long-term culture of normal human mammary epithelial cells.
Cancer Res 69(19):7557–7568
44. Wang F, Podell ER et al (2007) The POT1-TPP1 telomere
complex is a telomerase processivity factor. Nature
445(7127):506–510
45. Holysz H, Lipinska N et al (2013) Telomerase as a useful target
in cancer fighting-the breast cancer case. Tumour Biol
34(3):1371–1380
Breast Cancer Res Treat (2014) 145:581–591 591
123
